121470-24-4

Usage

Uses

Used in Respiratory Infections:
Azithromycin Monohydrate is used as an antibiotic for treating respiratory infections, such as bronchitis, pneumonia, and sinusitis. Its ability to target a wide range of bacteria, including Streptococcus pneumoniae and Haemophilus influenzae, makes it an effective treatment option for these conditions.
Used in Skin Infections:
In the dermatological field, Azithromycin Monohydrate is used as an antibiotic for treating skin infections, such as impetigo, cellulitis, and erysipelas. Its broad-spectrum activity against common skin pathogens, including Staphylococcus aureus and Streptococcus pyogenes, contributes to its effectiveness in managing these infections.
Used in Sexually Transmitted Diseases:
Azithromycin Monohydrate is used as a therapeutic agent for treating sexually transmitted diseases, such as chlamydia and gonorrhea. Its ability to target Neisseria gonorrhoeae and Chlamydia trachomatis, along with its convenient dosing regimen, makes it a preferred choice for the treatment of these infections.
Used in Various Formulations:
Azithromycin Monohydrate is available in a variety of formulations, including oral tablets, capsules, and liquid suspension, catering to different patient needs and preferences. This versatility allows for easier administration and improved patient compliance, ensuring effective treatment outcomes.
It is crucial to use Azithromycin Monohydrate only as prescribed by a healthcare professional to minimize the risk of antibiotic resistance and maintain its effectiveness over time. Proper use and adherence to the prescribed dosage and duration are essential for maximizing the drug's therapeutic benefits while minimizing potential side effects.

InChI:InChI=1S/C38H72N2O12.H2O/c1-15-27-38(10,46)31(42)24(6)40(13)19-20(2)17-36(8,45)33(52-35-29(41)26(39(11)12)16-21(3)48-35)22(4)30(23(5)34(44)50-27)51-28-18-37(9,47-14)32(43)25(7)49-28;/h20-33,35,41-43,45-46H,15-19H2,1-14H3;1H2/t20-,21-,22+,23-,24-,25+,26+,27-,28+,29-,30+,31-,32+,33-,35+,36-,37-,38-;/m1./s1

Upstream product

• 83905-01-5 Zithromax(R) 
• 7732-18-5 water 
• 76801-85-9 9-Deoxo-9a-aza-9a-homoerythromycin A 
• 50-00-0 formaldehyd 
• 117772-70-0 azithromycin dihydrate 

Downstream Products

• 117772-70-0 azithromycin Monohydrate 
• 117772-70-0 azithromycin dihydrate 

Relevant academic research and scientific papers

A PROCESS FOR PREPARING 9-DEOXO-9A-AZA-9A-HOMOERYTHROMYCIN A

The invention relates to a process for preparing 9-Deoxo-9a-aza-9a- homoerythromycin A of formula (III), which is an intermediate in the preparation of Azithromycin dihydrate.

Process of preparing a crystalline azithromycin monohydrate

The present invention provides a process of preparing a crystalline azithromycin monohydrate. The process involves dissolving azithromycin in a solution containing ethanol, adding the dissolved azithromycin into water to precipitate the crystals, isolating and drying the precipitate to a water content of about 5% (w/w) to about 7% (w/w). The resulting azithromycin monohydrate is stable, exhibiting less than 2% degradation, and non-hydroscopic.

PROCESS FOR PREPARING NON-HYGROSCOPIC AZITHROMYCIN DIHYDRATE

A direct, single step process for preparing a semi-synthetic antibiotic azithromycin dihydrate (non-hygroscopic) is provided, by in situ reductive N-methylation of azaerythromycin A and subsequent crystallization from a mixture of acetone and water, preferably together with a catalytical quantity of a base such as liquor ammonia, which comprises: a) reacting azaerythromycin A with formic acid and formaldehyde in an organic solvent medium, to form a reaction mass comprising N-methylated azaerythromycin A (i.e. azithromycin); b) adding aqueous alkali solution to the reaction mass to form an aqueous phase and an organic phase; c) (i) when the organic solvent medium is acetone, separating the aqueous phase from the acetone organic phase, and removing the aqueous phase; or (ii) when the organic solvent medium is a solvent other than acetone, separating the aqueous phase from the organic phase and removing the aqueous phase, optionally washing the separated organic phase with aqueous alkali solution, completely distilling off the solvent from the organic phase to leave a residue, and adding acetone to dissolve the residue and form an acetone organic phase; d) adding water, and optionally a base, to the acetone organic phase to form a mixture, and allowing crystals to form in the mixture; e) recovering the crystals from the mixture and optionally washing the crystals; f) drying the crystals to obtain non-hygroscopic azithromycin dihydrate, and the yield of the non-hygroscopic azithromycin dihydrate of a pharmaceutically acceptable quality is obtained in yields up to 78-82% w/w.

Stable non-dihydrate azithromycin oral suspensions

This invention relates to a powder for oral suspension, and an oral suspension made there from, which comprises non-dihydrate azithromycin and an azithromycin conversion stabilizing excipient, wherein said excipient reduces the conversion of the form of azithromycin, when placed in suspension, to another form of azithromycin. This invention further relates to a method for reducing the conversion of a form of non-dihydrate azithromycin, in an oral suspension, by adding a surface tension reducing excipient that reduces the surface tension of the aqueous vehicle. Furthermore, this invention relates to a method for reducing the conversion of a non-dihydrate azithromycin, in an unflavored oral suspension, by raising the viscosity of the oral suspension, and in a flavored oral suspension by lowering the viscosity of the oral suspension.

Process for preparation of anhydrous azithromycin

The present invention provides a stable form of azithromycin derivatives that act as antibiotics. These compounds are in anhydrous form and have increased stability over the hydrated forms.

Azithromycin preparation in its noncryst alline and crystalline dihydrate forms

The present invention describes new procedures for the preparation of the macrolide azithromycin in its non-crystalline and crystalline dihydrate forms, which are characterized and clearly differentiated by means of the following methods and techniques: 1. IR Spectroscopy. 2. Differential Scan Calorimetry (DSC). 3. X-Ray Diffraction. 4. Hygroscopicity. 5. Crystallinity test (Light Polarized Microscopy)

Azithromycin dihydrate

Non-hygroscopic, azithromycin (9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin) dihydrate and a process therefor.

Preparation of azithromycin dihydrate

Azithromycin dihydrate is prepared from azithromycin by adding a base to an aqueous solution of azithromycin to crystallise the dihydrate, the aqueous solution having a pH of from 1 to 5 and containing acetone.